Related Experiment Videos
Autolysis induction of malignant lymphoblasts.
Archivos De Investigacion Medica
|January 1, 1978
Summary
Epsilon aminocaproic acid (EACA) treatment showed significant L5178Y lymphoma tumor involution in mice. Higher EACA doses correlated with greater tumor reduction after treatment cessation.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- L5178Y lymphoma is an aggressive malignancy.
- Understanding therapeutic interventions for lymphoma is crucial.
Purpose of the Study:
- To investigate the efficacy of epsilon aminocaproic acid (EACA) in treating L5178Y lymphoma in BALB/C mice.
- To determine the dose-dependent relationship between EACA and tumor involution.
Main Methods:
- BALB/C mice received daily subcutaneous injections of EACA (0.1-3.2 mg/g) for six days post-lymphoma transplantation.
- Tumor response, including complete involution, was assessed 72 hours after EACA discontinuation.
- Control groups received no treatment.
Main Results:
- Complete tumor involution ranged from 20-90% for ascitic tumors and 50% for solid tumors.
- Tumor involution was directly proportional to the EACA dosage administered.
- Untreated control mice had a median survival of 10 days.
Conclusions:
- EACA demonstrates significant anti-lymphoma activity, leading to tumor involution.
- The mechanism may involve EACA's role as a proteolytic enzyme inhibitor, promoting malignant cell autolysis and macrophage phagocytosis post-treatment.
- EACA represents a potential therapeutic agent for lymphoma treatment.